BillionToOne, Inc. (BLLN) SEC Filings & Earnings Calls

Oncology segment growing faster but has higher cost-per-test, potentially pressuring gross margin if mix shifts further.

“Improvements in cost-per-test for both oncology and prenatal were offset by faster growth of oncology products, which have higher costs-per-test.”

Guidance reiteration implies no acceleration from current run-rate; Q2 annualized revenue $438M vs FY guidance midpoint $457.5M, leaving limited upside.

“Q2 annualized run-rate $438M vs FY guidance $450-465M; guidance reiterated, not raised.”

Payor concentration risk

“Third-party reimbursement for our tests represented more than 90% of our revenue for the six months ended June 30, 2026” · word for word

Oncology mix shift cost pressure

“Overall Cost Per Test increased 3% due to shift towards higher-cost oncology products”

Debt covenant risk

“We are required to maintain trailing six-month net revenue based on a schedule that gradually increases up to $120.0 million as of December 31, 2026, and a trailing six-month gross margin of not less than 30%.” · word for word

Lease obligation of $46.7M over 12 years adds fixed cost; execution risk on build-out and capacity utilization

“Aggregate base rent payments due over the 12-year term are approximately $46.7 million” · word for word

Oncology segment still small; rapid growth may not be sustainable; cost-per-test higher than prenatal.

“faster growth of our oncology products, which have higher costs-per-test.” · word for word

Dependence on payor contracts and reimbursement; $300M contracted lives but further expansion needed.

“significantly expanded our payor contracts, reaching $300 million contracted lives in the U.S.” · word for word

Dependence on third-party payor reimbursement

“Third-party reimbursement for our tests represented more than 90% of our revenue for the three months ended March 31, 2026.” · word for word

Accumulated deficit

“We have generated significant losses from operations and negative cash flows from operating activities in the past as reflected in our accumulated deficit of $256.8 million as of March 31, 2026.” · word for word

Debt obligations

“We have a debt facility with availability of up to $140.0 million... The advanced principal accrues interest at a rate of 8.0% per annum.” · word for word

Key Person Dependency

“CEO and CTO are co-founders with significant voting power (31.1% and 32.2% respectively).”

Reimbursement Dependency

“Reimbursement from third-party payors for our tests represented more than 90% of our revenue for each of the years ended December 31, 2025 and 2024.” · word for word

Supply Chain Concentration

“We rely on a limited number of suppliers or, in some cases, sole or single-source suppliers, for some of our laboratory instruments and materials.” · word for word

Material Weakness in Internal Controls

“We have identified material weaknesses in our internal control over financial reporting.” · word for word

Competitive Pressure

“Our competitors may offer oncology tests for therapy selection that encompass a broader range of genes, thereby positioning their products as more comprehensive.” · word for word

Regulatory and Legal Risks

“We have been, and in the future may be, involved in legal proceedings, regulatory investigations and inquiries and other legal matters.” · word for word

Rapid growth may strain operational capacity and quality control.

“Tests delivered +47% Y/Y; revenue +113% Y/Y”

Dependence on payer coverage expansion for continued growth.

“expanding payer coverage, and a growing base of providers choosing our tests” · word for word

Competitive pressure in molecular diagnostics market.

“next-generation molecular diagnostics company” · word for word

Guidance is forward-looking and subject to risks; no detailed assumptions provided.

“Forward-looking statements subject to risks and uncertainties; refer to Risk Factors in 10-Q.”

Reimbursement concentration risk

“Reimbursement from third-party payors for our tests represented more than 90% of our revenue for each of the years ended December 31, 2023 and 2024.” · word for word

Material weakness in internal controls

“We have identified material weaknesses in our internal control over financial reporting.” · word for word

Single facility dependency

“We currently derive nearly all of our revenue from tests performed at our laboratory facility located in Union City, California.” · word for word

Key person risk

“We do not maintain 'key person' insurance on any of our employees, including our Co-Founders.” · word for word

Supply chain concentration

“We rely on a limited number of suppliers or, in some cases, sole or single-source suppliers, for some of our laboratory instruments and materials.” · word for word

Dependence on continued volume and ASP growth; competitive molecular diagnostics market.

“Forward-looking statements reference risks in prospectus; no new specific risks disclosed.”